Skip to main content
SpringerLink
Log in

Pembrolizumab in head and neck cancer cost effective in US, not in China

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Lang Y, et al. Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis. Clinical Drug Investigation : 23 Oct 2020. Available from: URL: https://doi.org/10.1007/s40261-020-00973-9

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pembrolizumab in head and neck cancer cost effective in US, not in China. PharmacoEcon Outcomes News 865, 25 (2020). https://doi.org/10.1007/s40274-020-7249-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7249-8

Search

Navigation